Table 4.
Active clinical trials of systemic treatment for periocular malignancies.
| ClinicalTrials.gov ID | Disease of Interest | Disease Stage | Treatment |
|---|---|---|---|
| NCT04154943 | Cutaneous SCC | Resectable stage II-IV | Neoadjuvant cemiplimab q3w for up to 4c |
| NCT04710498 | Cutaneous SCC | Resectable locally advanced | Neoadjuvant atezolizumab q3w for 3c |
| NCT04808999 | Cutaneous SCC | Resectable stage II-IV | Neoadjuvant pembrolizumab q3w for 2c, then adjuvant pembrolizumab for 15c |
| NCT05025813 | Cutaneous SCC | Resectable stage II-IV | Neoadjuvant pembrolizumab q3w for 4c, then surgery +/- EBRT, then adjuvant pembrolizumab for 17c |
| NCT04315701 | Cutaneous SCC | Resectable stage I-III | Neoadjuvant cemiplimab q3w for up to 3c |
| NCT04620200 | Cutaneous SCC | Resectable stage II-IVa | Neoadjuvant nivolumab +/- ipilimumab q2w for 2c |
| NCT04428671 | Cutaneous SCC | Resectable high-risk disease | Neoadjuvant cemiplimab q3w for up to 3c, then adjuvant cemiplimab q3w for up to 18c |
| NCT04975152 | Cutaneous SCC | Resectable stage II-IV | Neoadjuvant cemiplimab q3w for up to 9c, then adjuvant cemiplimab q3w for up to 8c |
| NCT02324608 | Cutaneous SCC | Resectable high-risk disease | Neoadjuvant cetuximab weekly for 8w |
| NCT03035188 | Basal cell carcinoma | Resectable large (>2 cm) disease | Neoadjuvant vismodegib daily for up to 12w |
| NCT04323202 | Basal cell carcinoma | Resectable large (>2 cm) disease | Neoadjuvant pembrolizumab q3w for 4c, then adjuvant pembrolizumab for 13c |
| NCT03534947 | Basal cell carcinoma | Resectable cosmetically challenging disease | Neoadjuvant sonidegib for 12w, then imiquimod for 6w or surgery or best supportive care |
| NCT05496036 | Merkel cell carcinoma | Resectable stage I-III | Neoadjuvant pembrolizumab 400 mg for 1c, then adjuvant pembrolizumab for 1 year |
| NCT04869137 | Merkel cell carcinoma | Resectable stage II-IV | Neoadjuvant pembrolizumab q3w for 2c + lenvatinib, then surgery +/- adjuvant radiotherapy, then adjuvant pembrolizumab for 17c |
| NCT04975152 | Merkel cell carcinoma | Resectable stage I-II | Neoadjuvant cemiplimab q3w for 9c, then adjuvant cemiplimab for up to 8c |
| NCT04020809 | Melanoma | Resectable stage I-II | Neoadjuvant atezolizumab q3w for 2c |
SCC, squamous cell carcinoma; q, every; w, week; c, cycle; EBRT, external beam radiotherapy.